Gate Update: Industry-First Japanese Stock Launch, Record SOL Staking, And Top-Tier Rankings Define A Landmark Week For Gate
Gate’s most eventful week in current reminiscence opened on three fronts without delay. Moderna (MRNA) surged 177% intraday after Phase 3 trial outcomes for its personalised mRNA melanoma vaccine made headlines, sending Gate’s MRNA perpetual futures into the highest three globally by open curiosity. Simultaneously, the platform made an industry-first transfer by launching Japanese inventory…
